Large Risk Reduction For Rivaroxaban In Blood Clot Prevention
/
RSS Feed
Bengt Eriksson
REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta
BENGT ERIKSSON, Gothenburg University
In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when compared to enoxaparin. Derek Thorne heard more from Bengt Eriksson of Gothenburg University.
BENGT ERIKSSON, Gothenburg University
In a large phase III trial of patients having a hip replacement, the oral anticoagulant rivaroxaban has shown significant benefit when compared to enoxaparin. Derek Thorne heard more from Bengt Eriksson of Gothenburg University.
You may also like...
Elective Single Embryo Transfer in IVF: 13 Year Data From Sweden – reporting from European Society of Human Reproduction and Embryology 23rd Annual Meeting, Lyon, July 1-4, 2007 2 Jul, 2007 - Audio Journal of General Medicine – H5 N1 Avian Flu: Europe Ready? 22 Apr, 2006
- Best Evidence Yet that Folic Acid Fortification Reduces Neural-Tube Defects 2 Aug, 2007
- Bortezomib for Multiple Myeloma Can Cause Reactivation of Viruses 19 Sep, 2007
I am a medicine student in Turkey and I am hoping to have my specialty in Orthotics. I am really glad to listen such a nice podcast about current progresses in the field, I hope I can make similar research in the field as well.